Phase Scientific

Executive Summary

Phase Scientific Americas, a Los Angeles-based biotechnology company spun out of UCLA in 2015, focuses on developing and commercializing accessible rapid antigen tests for both consumers and healthcare professionals. The company aims to democratize diagnostic testing by providing science-based tools that empower individuals to manage their health. Operating in the competitive diagnostics market, Phase Scientific differentiates itself through innovation in rapid testing technology, targeting point-of-care and at-home use cases. Despite being private and early-stage with limited public data, the company has a clear mission and potential to capture market share in the growing rapid diagnostics segment, particularly as demand for convenient testing persists post-pandemic. However, the lack of disclosed funding, revenue, or regulatory milestones introduces uncertainty, and the company faces stiff competition from established players and newer entrants with similar offerings.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation rapid antigen test with improved sensitivity40% success
• Q2 2026Strategic distribution partnership with a major pharmacy chain or healthcare distributor30% success
• Q4 2026Series A or seed funding round to scale manufacturing and R&D50% success